Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Colorectal cancer (CRC) is the third and second most common cancer in males and females worldwide, respectively.
Spondin-2
is a conserved secreted extracellular matrix protein and a candidate cancer biomarker. Here we found that
Spondin-2
mRNA was upregulated in CRC tissues using quantitative RT-PCR and data-mining of public Oncomine microarray datasets.
Spondin-2
protein was increased in CRC tissues, as revealed by immunohistochemistry analyses of two tissue microarrays containing 180 cases.
Spondin-2
gene expression was significantly associated with CRC stage, T stage, M stage and Dukes stage, while its protein was associated with age and M stage. Kaplan-Meier analysis revealed that the upregulated
Spondin-2
mRNA and protein predicted poor prognosis of CRC patients. Univariate and multivariate Cox regression analyses indicated that grade, recurrence, N stage and high
Spondin-2
were independent predictors of overall survival of CRC patients. ELISA revealed that plasma
Spondin-2
was upregulated in CRC and dropped after surgery. Receiver operating characteristic curve analysis demonstrated that plasma
Spondin-2
has superior predictive performance for CRC with an area under the curve of 0.959 and the best sensitivity/specificity of 100%/90%. Furthermore, ectopic expression of
Spondin-2
enhanced
colon cancer
cell proliferation.
Spondin-2
could be an independent diagnostic and prognostic biomarker of
colon cancer
.
...
PMID:Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. 2594 35
Mindin
is important in broad spectrum of immune responses. On the other hand, we previously reported that mindin attenuated human
colon cancer
development by blocking angiogenesis through Egr-1-mediated regulation. However, the mice original mindin directly suppressed the syngenic colorectal cancer (CRC) growth in our recent study and we aimed to further define the role of mindin during CRC development in mice. We established the mouse syngeneic CRC CMT93 and CT26 WT cell lines with stable mindin knock-down or overexpression. These cells were also subcutaneously injected into C57BL/6 and BALB/c mice as well as established a colitis-associated colorectal cancer (CAC) mouse model treated with lentiviral-based overexpression and knocked-down of mindin. Furthermore, we generated mindin knockout mice using a CRISPR-Cas9 system with CAC model. Our data showed that overexpression of mindin suppressed cell proliferation in both of CMT93 and CT26 WT
colon cancer
cell lines, while the silencing of mindin promoted in vitro cell proliferation via the ERK and c-Fos pathways and cell cycle control. Moreover, the overexpression of mindin significantly suppressed in vivo tumour growth in both the subcutaneous transplantation and the AOM/DSS-induced CAC models. Consistently, the silencing of mindin reversed these in vivo observations. Expectedly, the tumour growth was promoted in the CAC model on mindin-deficient mice. Thus, mindin plays a direct tumour suppressive function during
colon cancer
progression and suggesting that mindin might be exploited as a therapeutic target for CRC.
...
PMID:Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice. 3261 21